A Potent Microglial Response to Blocking the CD47-Sirpα Anti-Phagocytic Axis Overcomes Deficient Macrophage Recruitment during Anti-CD47 Immunotherapy Against Glioblastoma

Aims: Modulation of tumor-associated macrophages and microglia (TAMs) in glioblastoma (GBM) poses a strategy to overcome the disease. But little is known about the composition of the TAM-pool and the role of GBM subtypes in shaping their immunologic environment. We sought to decipher the contribution of microglia and macrophages to the GBM-TAM-pool and their response to myeloid modulation such as CD47-Sirpa disruption with CD47 blocking antibodies.

Methods: We generated immunodeficient mice with color-coded macrophages and microglia termed Ccr2Rfp/+Cx3cr1Gfp+- NSG-mice as well as Ccr2Rfp/RfpCx3cr1Gfp+- NSG-mice devoid of macrophage influx into the brain. Mice were grafted with GBM cell lines expressing EBFP2-luciferase, and treated with humanized anti-CD47 antibodies. At endpoint, tumors FACS analyzed and both TAM subsets sorted for RNAseq analysis. Plasma cytokines were assessed. Mice were imaged using cranial window technology and 2-photon microscopy to monitor microglial and macrophage phagocytosis upon anti-CD47 treatment in real time.

Results: We identified a GBM subtype dependent composition of the TAM pool. While microglial TAMs were dominant in slow growing tumors, high passaged GBM cell lines of various subtypes induced a mixed pool still depending on GBM subtype. Anti-CD47 treatment let to macrophage and microglial phagocytosis and a microglial morphology change assessed by intracranial in vivo imaging and FACS. Furthermore, anti-CD47 treatment led to macrophage recruitment and vascular egress to the tumor site in a Ccr2 independent manner. Sirpa-CD47 blockade in context of Ccr2 deficiency was accompanied by a strong proinflammatory cytokine profile. Anti-CD47 treatment significantly improved survival of tumor burdened mice in presence or absence of peripheral macrophages. RNAseq analysis of sorted macrophages and microglia after anti-CD47 treatment revealed a transcriptional profile change toward a proinflammatory and M1-polarized signature in macrophages, whereas microglia displayed a loss of M2-related genes.

Conclusion: These results emphasize the importance of both resident microglia and invading macrophages in GBM biology. Microglia by themselves are amenable to anti-CD47 treatment and act as phagocytic effector cells that reduce GBM growth and improves survival. Moreover, CD47-Sirpa disruption caused an important phenotypic and functional status change of resident microglia, which will have implications for CNS immunotherapies in the future.

 

MissingLinkText

No conflict of interest has been declared by the author(s).